Right model.
Real experts.
Validated insight.
Breaking News:
InVivo Biosystems announces groundbreaking innovation in preclinical development.
Since welcoming new leadership in May 2024, InVivo Biosystems is driving breakthroughs in preclinical drug discovery and development. Discover how we’ve built our comprehensive, end-to-end platform.
Bridge the data gap between cell culture and rodent models. Rapidly conduct preclinical studies to de-risk your clinical trial.
InVivo Biosystems holds 10 global patents for CRISPR and other genome editing technologies. Our cutting-edge tools offer human-relevant insights into various diseases, driving preclinical drug discovery and development for pharmaceutical companies and beyond.
Discover the Future of Preclinical Development and Genetics on Our Blog!
Dive into the fascinating world of genetics and explore the groundbreaking advancements in preclinical development with our blog. Whether you’re a curious mind or a seasoned scientist, our blog is your gateway to understanding the research that’s shaping the future of biotech. From innovative model organisms to transformative insights into CNS diseases, we’re making the complex accessible and exciting. Join us on this journey of discovery and innovation—your next big idea might just be a click away!
About InVivo Biosystems
2010
Year Established
45
Number of Employees
11
Number of PhDs on Staff
19
Average Years of Experience in Genetics
4000+
Number of Preclinical Models Created
268
Publications
READY TO GET STARTED?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.